» Articles » PMID: 39065807

Introducing the NUATEI Consortium: A Mexican Research Program for the Identification of Natural and Synthetic Antimicrobial Compounds for Prevalent Infectious Diseases

Overview
Publisher MDPI
Specialty Chemistry
Date 2024 Jul 27
PMID 39065807
Authors
Affiliations
Soon will be listed here.
Abstract

The need for new drugs to treat human infections is a global health concern. Diseases like tuberculosis, trypanosomiasis, amoebiasis, and AIDS remain significant problems, especially in developing countries like Mexico. Despite existing treatments, issues such as resistance and adverse effects drive the search for new alternatives. Herein, we introduce the NUATEI research consortium, made up of experts from the Institute of Biomedical Research at UNAM, who identify and obtain natural and synthetic compounds and test their effects against human pathogens using in vitro and in vivo models. The consortium has evaluated hundreds of natural extracts and compounds against the pathogens causing tuberculosis, trypanosomiasis, amoebiasis, and AIDS, rendering promising results, including a patent with potential for preclinical studies. This paper presents the rationale behind the formation of this consortium, as well as its objectives and strategies, emphasizing the importance of natural and synthetic products as sources of antimicrobial compounds and the relevance of the diseases studied. Finally, we briefly describe the methods of the evaluation of the compounds in each biological model and the main achievements. The potential of the consortium to screen numerous compounds and identify new therapeutic agents is highlighted, demonstrating its significant contribution to addressing these infectious diseases.

References
1.
Miller L, Su X . Artemisinin: discovery from the Chinese herbal garden. Cell. 2011; 146(6):855-8. PMC: 3414217. DOI: 10.1016/j.cell.2011.08.024. View

2.
de Castro E, Reus T, de Aguiar A, Avila A, Souza T . Procaspase-activating compound-1 induces apoptosis in Trypanosoma cruzi. Apoptosis. 2017; 22(12):1564-1577. DOI: 10.1007/s10495-017-1428-5. View

3.
Cardenas-Guerra R, Moreno-Gutierrez D, Vargas-Dorantes O, Espinoza B, Hernandez-Garcia A . Delivery of Antisense DNA into Pathogenic Parasite Using Virus-Like Protein-Based Nanoparticles. Nucleic Acid Ther. 2020; 30(6):392-401. DOI: 10.1089/nat.2020.0870. View

4.
Martinez R, Espitia-Pinzon C, Silva Miranda M, Chavez-Santos R, Pretelin-Castillo G, Ramos-Orea A . Synthesis and antituberculosis activity of new acylthiosemicarbazides designed by structural modification. Drug Dev Res. 2019; 81(3):350-355. DOI: 10.1002/ddr.21626. View

5.
Gonzales M, Dans L, Sio-Aguilar J . Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev. 2019; 1:CD006085. PMC: 6326239. DOI: 10.1002/14651858.CD006085.pub3. View